Patents by Inventor Catherine Rougeot

Catherine Rougeot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions containing peptides derived from human BPLP protein
    Patent number: 9714951
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: July 25, 2017
    Assignee: INSTITUT PASTEUR
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES
    Publication number: 20160341744
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject
    Type: Application
    Filed: June 30, 2016
    Publication date: November 24, 2016
    Applicant: INSTITUT PASTEUR
    Inventors: Catherine ROUGEOT, Jean-Francois HUAULME, Marie-Noelle UNGEHEUER, Anne WISNER, Evelyne DUFOUR
  • Methods for treating pain by administering peptides derived from human basic proline-rich lacrimal protein
    Patent number: 9403871
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 2, 2016
    Assignee: INSTITUT PASTEUR
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
    Patent number: 9273094
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: March 1, 2016
    Assignee: INSTITUT PASTEUR
    Inventor: Catherine Rougeot
  • OPIORPHIN FOR USE AS A PSYCHOSTIMULANT AGENT
    Publication number: 20150329608
    Abstract: The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder.
    Type: Application
    Filed: June 4, 2015
    Publication date: November 19, 2015
    Applicant: INSTITUT PASTEUR
    Inventor: Catherine ROUGEOT
  • OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES
    Publication number: 20150065683
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Application
    Filed: November 11, 2014
    Publication date: March 5, 2015
    Applicant: INSTITUT PASTEUR
    Inventor: Catherine ROUGEOT
  • PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES
    Publication number: 20140349946
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject
    Type: Application
    Filed: May 19, 2014
    Publication date: November 27, 2014
    Applicant: INSTITUT PASTEUR
    Inventors: Catherine ROUGEOT, Jean-Francois HUAULME, Marie-Noelle UNGEHEUER, Anne WISNER, Evelyne DUFOUR
  • Method for detecting human BPLP protein or a maturation product thereof
    Patent number: 8895251
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: November 25, 2014
    Assignee: Institut Pasteur
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
    Patent number: 8889827
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: November 18, 2014
    Assignee: Institut Pasteur
    Inventor: Catherine Rougeot
  • USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER
    Publication number: 20140193843
    Abstract: The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use.
    Type: Application
    Filed: February 14, 2014
    Publication date: July 10, 2014
    Applicant: Institut Pasteur
    Inventors: Catherine ROUGEOT, Evelyne Dufour, Sylvie Villard-Saussine, Marie-Noelle Ungeheuer, Pierre Jouannet
  • Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
    Patent number: 8642729
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: February 4, 2014
    Assignee: Institut Pasteur
    Inventor: Catherine Rougeot
  • Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
    Patent number: 8168770
    Abstract: A method of preventing or inhibiting infection by a parasite or virus in vivo comprising administering to a human in need thereof a parasite or virus mitogen in a sub-mitogenic amount sufficient to induce a protective immune response against the parasite or virus in the human.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: May 1, 2012
    Assignees: Centre National de la Recherche Scientifique, Instituto Gulbekian De Cienca
    Inventors: Paolo Minoprio, Mario Arala-Chaves, Eduarda Maria Santos Dores Arala Chaves, legal representative, Rui Mario Dores Arala Chaves, legal representative, Antonio Coutinho, Bernardo Reina San Martin, Catherine Rougeot, Wim Degrave, Alain Cosson
  • USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER
    Publication number: 20120034604
    Abstract: The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use.
    Type: Application
    Filed: November 27, 2009
    Publication date: February 9, 2012
    Applicant: INSTITUT PASTEUR
    Inventors: Catherine Rougeot, Evelyne Dufour, Sylvie Villard-Saussine, Marie-Noelle Ungeheuer, Pierre Jouannet
  • PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES
    Publication number: 20110244491
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Application
    Filed: May 6, 2011
    Publication date: October 6, 2011
    Applicant: INSTITUT PASTEUR
    Inventors: Catherine ROUGEOT, Jean-Francois Huaulme, Marie-Noëlle Ungeheuer, Anne Wisner, Evelyne Dufour
  • Peptides derived from human BPLP protein
    Patent number: 8017571
    Abstract: The invention relates to a peptide that is a maturation product of the Basic Prolin-rich Lacrinal Protein (BPLP) or a peptide derivative of said maturation product, wherein the peptide or peptide derivative exhibits an inhibitory property against a metallo-ectopeptidase, especially NEP and/or APN. The present invention also relates to polynucleotides coding for said peptides and to antibodies directed against said peptides. Furthermore, the present invention relates to diagnostic and therapeutic uses of human BPLP protein and inhibitory peptides derived therefrom, polypeptides coding for human BPLP protein or peptides derived therefrom as well as antibodies directed against BPLP protein or peptides derived therefrom.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: September 13, 2011
    Assignee: Institut Pasteur
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • OPIORPHIN FOR USE AS A PSYCHOSTIMULANT AGENT
    Publication number: 20110178021
    Abstract: The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder.
    Type: Application
    Filed: May 26, 2009
    Publication date: July 21, 2011
    Applicant: INSTITUT PASTEUR
    Inventor: Catherine Rougeot
  • OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES
    Publication number: 20110124571
    Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.
    Type: Application
    Filed: April 7, 2009
    Publication date: May 26, 2011
    Applicant: INSTITUT PASTEUR
    Inventor: Catherine Rougeot
  • Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
    Patent number: 7851603
    Abstract: A method of preventing or inhibiting infection by a parasite or virus in vivo comprising administering to a human in need thereof a parasite or virus mitogen in a sub-mitogenic amount sufficient to induce a protective immune response against the parasite or virus in the human.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: December 14, 2010
    Assignees: Centre National de la Recherche Scientifique, Instituto Gulbenkian de Cienca
    Inventors: Paolo Minoprio, Mario Arala-Chaves, Sara Isabel Mansinho Fernandes de Almeida, legal representative, Antonio Coutinho, Bernardo Reina San Martin, Catherine Rougeot, Wim Degrave, Alain Cosson
  • Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
    Patent number: 7732563
    Abstract: A method of preventing or inhibiting infection by a parasite or virus in vivo comprising administering to a human in need thereof a parasite or virus mitogen, such as a eukaryotic amino acid racemase, in a sub-mitogenic amount sufficient to induce a protective immune response against the parasite or virus in the human.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: June 8, 2010
    Assignee: Institut Pasteur
    Inventors: Paola Minoprio, Mario Arala-Chaves, Sara Isabel Mansinho Fernandes de Almeida, legal representative, Antonio Coutinho, Bernardo Reina San Martin, Catherine Rougeot, Wim Degrave, Alain Cosson
  • PROCESS FOR IDENTIFYING A LIGAND THAT BINDS TO THE NEP BINDING SITE FOR THE SMR1 PENTAPEPTIDE
    Publication number: 20100041072
    Abstract: The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human.
    Type: Application
    Filed: October 16, 2009
    Publication date: February 18, 2010
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scient.
    Inventors: Catherine Rougeot, Francois Rougeon